Search

Displaying results 8221 - 8230 of 10000 in total
  1. Drug

    COVID-19 convalescent plasma

    go.drugbank.com/drugs/DB15692
    Investigational

    [L14333] This investigational COVID-19 treatment is currently available through three main pathways: use in registered clinical trials, use through the expanded access COVID-19 protocol (21 CFR 312.305 … clinical trial results for the safety or efficacy of COVID-19 convalescent plasma, early results from 5000 patients under the FDA expanded access program suggest that convalescent plasma transfusion in

  2. Drug

    Streptococcus pneumoniae type 8 capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB16713
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … Streptococcus pneumoniae type 8 capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae*

  3. Drug

    Streptococcus pneumoniae type 11A capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB16715
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … Streptococcus pneumoniae type 11A capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae

  4. Drug

    Streptococcus pneumoniae type 15A capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB19343
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … Streptococcus pneumoniae type 15A capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of _Streptococcus pneumoniae

  5. Drug

    Streptococcus pneumoniae type 17F capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB19346
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … Streptococcus pneumoniae type 17F capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of _Streptococcus pneumoniae

  6. Drug

    Streptococcus pneumoniae type 20A capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB19347
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … Streptococcus pneumoniae type 20A capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of _Streptococcus pneumoniae

  7. Drug

    BNT162a1 SARS-CoV-2 Vaccine

    go.drugbank.com/drugs/DB15697
    Experimental

    [L15002, L15007] BNT162a1 is undergoing evaluation in clinical trials in both the USA (NCT04368728) and Germany (NCT04380701).[L15017, L15022] … [L15002, L15007] BNT162a1 is a uridine mRNA (uRNA) vaccine formulated in lipid nanoparticles for delivery via intramuscular injection.

  8. Drug

    BNT162c2 SARS-CoV-2 Vaccine

    go.drugbank.com/drugs/DB15698
    Experimental

    [L15002, L15007] BNT162c2 is undergoing evaluation in clinical trials in both the USA (NCT04368728) and Germany (NCT04380701).[L15017, L15022] … [L15002, L15007] BNT162c2 is a self-amplifying mRNA (saRNA) vaccine formulated in lipid nanoparticles for delivery via intramuscular injection.

  9. Drug

    VM4-037

    go.drugbank.com/drugs/DB15319
    Investigational

    VM4-037 is under investigation in clinical trial NCT00884520 (An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037).

  10. Drug

    Glafenine

    go.drugbank.com/drugs/DB08963
    ApprovedWithdrawn

    An anthranilic acid derivative with analgesic properties used for the relief of all types of pain. Glafenine is withdrawn from the American market.